ОЦЕНКА ЭФФЕКТИВНОСТИ РЕПЕРФУЗИИ ПРИ ОСТРОМ ИНФАРКТЕ МИОКАРДА: СОВРЕМЕННЫЕ КОНЦЕПЦИИ И МЕТОДЫ

1. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99(21): 2720-32.

2. Braunwald E., Maroko P.R. The reduction of infarct size: an idea whose time (for testing) has come. Circulation. 1974; 50(2): 206-9.

3. Califf R., O'Neil W., Stack R., et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann. Intern. Med. 1988; 108(5): 658-662.

4. Chiladakis J.A., Vlachos N., Patsouras N., et al. Usefulness of reperfusion ventricular arrhythmias in non-invasive prediction of early reperfusion and sustained coronary artery patency in acute myocardial infarction. J. Thromb. Thrombolysis. 2001; 12(3): 231-6.

5. Christenson R.H., Ohman E.M., Topi E.J., et al. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. Circulation 1997; 96(6): 1776-1782.

6. de Lemos J.A., Antman E.M., McCabe C.H., et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am. J. Cardiol. 2000; 85(3): 299-304.

7. de Lemos J.A., Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J. Am. Coll. Cardiol 2001; 38(5): 1238-94.

8. Eeckhout E., Kern M.J. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur. Heart. J. 2001; 22(9): 729-739.

9. Ellis S.G., Da Silva E.R., Spaulding C.M., et al. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am. Heart. J. 2000; 139(6): 1046-53.

10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994; 343(8893): 311-22.

11. French J.K., Ramanthan K., Stewart J.T., et al. A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. Am. Heart. J. 2003; 145(3): 508-14.

12. Ganz W., Buchbinder N., Marcus H., et al. Intracoronary thrombolysis in evolving myocardial infarction. Am. Heart. J. 1981; 101(1): 4-13.

13. Gibson С.М., Cannon С.Р., Daley W.L., et al. TIMI frame count. A quantitative method of assessing coronary artery flow. Circulation. 1996; 93(5): 879-888.

14. Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85(5): 1699-705.

15. Kaul S. Myocardial contrast echocardiography. Current Problems in Cardiology. 1997; 22(11): 553-635.

16. Kloner R.A., Ganote C.E., Jennings R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974; 54(6): 1496-508.

17. Kondo M., Nakano A., Saito D., Shimono Y. Assessment of "microvascular no-reflow phenomenon" using Technecium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 1998; 32(4): 898-903.

18. Laperche T., Steg P., Dehoux M., et al. A study of biochemical markers of reperfusion early after thrombolysis for acute myocardial infarction. Circulation. 1995; 92(8): 2079-86.

19. Lincoff A.M., Topol E.J. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993; 88(3): 1361-74.

20. Maroko P.R., Kjekshus J.K., Sobel B.E., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971; 43(l): 67-82.

21. Morishima I., Sone T., Okumura K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first anterior myocardial infarction. J. Am. Coll. Cardiol. 2000; 36(4): 1202-1209.

22. Reimer K.A., Lowe J.E., Rasmussen M.M., Jennings R.B. The wave-front phenomenon of ischemic cell death: myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation. 1977; 56(7): 786-94.

23. Rezkalla S.H., Kloner R.A. No-reflow phenomenon. Circulation. 2002; 105(5): 656-662.

24. Roe M.T., Ohman E.M., Maas A.C.P., et al. Shifting the open artery hypothesis downstream: the quest for optimal reperfusion. J. Am. Coll. Cardiol. 2001; 37(1): 9-18.

25. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. Circulation. 1998; 97(16): 1549-56.

26. Santoro G.M., Valenti R., Buonamici P., et al. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am. J. Cardiol. 1998; 82(8): 932-7.

27. Schroeder K., Wegscheider K, Zeymer U., Schroeder R. Extent of ST-segment deviation in the single ECG lead of maximum deviation present 90 or 180 minutes after start of thrombolytic therapy best predicts outcome in acute myocardial infarction. Z. Kardiol. 2001; 90(8): 557-567.

28. Schroeder K., Wegscheider K., Zeymer U., Schroeder R. Prediction of long-term outcome by the extent of the existing ST-segment deviation in a single electrocardiographic lead shortly after thrombolysis in acute myocardial infarction. Am. J. Cardiol. 2003; 91(4): 454-456.

29. Simes R.J., Topol E.J., Holmes D.R., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995; 91(7): 1923-8.

30. Stewart J., French J., Theroux P., et al. Early non-invasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J. Am. Coll. Cardiol. 1998; 31(7): 1499-1505.

31. Tanasijevic M.J., Cannon P.C., Wybenga D.R., et al. Myoglobin, creatine kinase MB, and cardiac troponin-I assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am. Heart. J. 1997; 134(4): 622-30.

32. The GUSTO-I Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N. Engl. J. Med. 1993; 329(22): 1615-22.

33. The Thrombolysis in Myocardial Infarction (TIMI) trial, phase I findngs: TIMI Study Group. N. Engl. J. Med. 1985; 312(14). R932-936.

34. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation. 1995; 91(10): 2862-4.

35. van der Laarse A., van der Wall E.E., van den Pol R.C., et al. Rapid enzyme release from acutely infracted myocardium after early thrombolytic therapy: washout or reperfusion damage? Am. Heart. J. 1988; 115(4): 711-6.

36. van't Hof A., Liem A., de Boer M., Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 1997; 350(9078): 615-9.

37. van't Hof A.W.J., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Myocardial blush grade. Circulation 1998; 97(23): 2302-2306.

38. Verheugt F.W., Meijer A., Lagrand W.K., Van Eenige M.J. Reocclusion: the flip side of coronary thrombolys. is. J. Am. Coll. Cardiol. 1996; 27(4): 766-73.

39. Zabel M., Hohnloser S.H., Koster W., et al. Analysis of creatine kinase-MB, myoglobin, and Troponin-T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation 1993; 87(5): 1542-50.

40. Zeymer U., Schroeder R., Neuhaus K.L. Noninvasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction: results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur. Heart. J. 2001; 22(9): 769-75.